{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:26:53Z","timestamp":1792895213582,"version":"4.5.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Few live microbial therapeutics have demonstrated conclusive or reproducible clinical efficacy. Cochrane meta-analyses of probiotic interventions across multiple clinical trials, analyzed using a rank-biserial correlation test, revealed that intestinal inflammation is negatively correlated with clinical responsiveness. This is exemplified by\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    Nissle 1917, which shows efficacy in maintaining remission comparable to frontline therapies, yet fails to demonstrate clear benefit in the treatment of active ulcerative colitis, an inflammatory bowel disease defined by chronic intestinal inflammation. Beyond inflammation as a key barrier to efficacy, inadequate shelf life and delivery strategies further compromise microbial viability and functional persistence in the gastrointestinal tract. Here, we highlight both the challenges and emerging opportunities in the field of live microbial therapeutics, emphasizing the urgent need to integrate scientific, clinical, and industrial efforts to achieve durable and clinically meaningful outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2025.1695976","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:21:55Z","timestamp":1762320115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Not quite a cure yet: unlocking the unfulfilled promise of live biotherapeutics for disease treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Andrea","family":"Verdugo-Meza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han M.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeran A.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna L.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ajhp\/zxae249","article-title":"Human microbiome: Impact of newly approved treatments on C. difficile infection","volume":"82","author":"Bland","year":"2025","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jmii.2020.03.029","article-title":"Lactobacillus rhamnosus sepsis associated with probiotic therapy in an extremely preterm infant: pathogenesis and a review for clinicians","volume":"54","author":"Chiang","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B2","unstructured":"A phase 2a randomized, placebo-controlled, double-blind, multi-center dose escalation study, to evaluate the safety, tolerability, pharmacodynamics and efficacy of AG011, in subjects with moderately active ulcerative colitis\n          \n          \n          2009"},{"key":"B3","volume-title":"A phase 3, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of SYNB1934 in patients with PKU (SYNPHENY-3)","year":"2023"},{"key":"B4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1046\/j.1365-3083.2002.01005.x","article-title":"Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain nissle 1917","volume":"55","author":"Cukrowska","year":"2002","journal-title":"Scand. J. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1097\/MCG.0000000000000235","article-title":"Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model","volume":"48","author":"del Carmen","year":"2014","journal-title":"J. Clin. Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/d43747-020-01178-x","article-title":"Early investments powering the ascent of microbiome therapeutics biopharma dealmakers","author":"Eisenstein","year":"2020","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1038\/s41598-018-23180-1","article-title":"Probiotic Escherichia coli inhibits biofilm formation of pathogenic E. coli via extracellular activity of DegP","volume":"8","author":"Fang","year":"2018","journal-title":"Sci. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s44222-022-00010-8","article-title":"Bioinspired nanotopographical design of drug delivery systems","volume":"1","author":"Finbloom","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"key":"B9","volume-title":"Probiotic compositions and uses thereof","author":"Gibson","year":"2018"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1128\/JB.184.21.5912-5925.2002","article-title":"A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain nissle 1917","volume":"184","author":"Grozdanov","year":"2002","journal-title":"J. Bacteriol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/1753425910396251","article-title":"Anti-inflammatory modulation of immune response by probiotic Escherichia coli nissle 1917 in human blood mononuclear cells","volume":"18","author":"G\u00fcttsches","year":"2012","journal-title":"Innate Immun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1128\/IAI.01406-09","article-title":"The K5 capsule of Escherichia coli strain nissle 1917 is important in stimulating expression of toll-like receptor 5, CD14, MyD88, and TRIF together with the induction of Interleukin-8 expression via the mitogen-activated protein kinase pathway in epithelial cells","volume":"78","author":"Hafez","year":"2010","journal-title":"Infect. Immun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.tibtech.2021.08.002","article-title":"Discovery and delivery strategies for engineered live biotherapeutic products","volume":"40","author":"Heavey","year":"2022","journal-title":"Trends Biotechnol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1055\/s-2008-1027463","article-title":"Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study","volume":"46","author":"Henker","year":"2008","journal-title":"Z. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ibd.21042","article-title":"Survival of the probiotic Escherichia coli nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers","volume":"16","author":"Joeres-Nguyen-Xuan","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005573.pub3","article-title":"Probiotics for induction of remission in ulcerative colitis","volume":"3","author":"Kaur","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7060","DOI":"10.1038\/s41467-025-62349-x","article-title":"A multicellular self-organized probiotic platform for oral delivery enhances intestinal colonization","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.15403\/jgld.2014.1121.244.ecn","article-title":"Escherichia coli nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysis","volume":"24","author":"Losurdo","year":"2015","journal-title":"J. Gastrointestin Liver Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"11688","DOI":"10.3390\/ijms241411688","article-title":"Antibacterial MccM as the major microcin in Escherichia coli nissle 1917 against pathogenic enterobacteria","volume":"24","author":"Ma","year":"2023","journal-title":"IJMS"},{"key":"B19","unstructured":"Microbiome therapeutics market revenues to double by 2030 - key opportunities lie in live-biotherapeutics, personalized medicine, and digital health integrations GLOBE NEWSWIRE\n          \n          \n          2025"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41564-021-00920-0","article-title":"Probiotics impact the antibiotic resistance gene reservoir along the human GI tract in a person-specific and antibiotic-dependent manner","volume":"6","author":"Montassier","year":"2021","journal-title":"Nat. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17324","DOI":"10.1038\/srep17324","article-title":"Escherichia coli nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance","volume":"5","author":"Nzakizwanayo","year":"2015","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.3390\/ijms25105338","article-title":"Modulation of serotonin-related genes by extracellular vesicles of the probiotic Escherichia coli nissle 1917 in the Interleukin-1\u03b2-Induced inflammation model of intestinal epithelial cells","volume":"25","author":"Olivo-Mart\u00ednez","year":"2024","journal-title":"IJMS"},{"key":"B23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.15403\/jgld-5660","article-title":"Response to letter to editor on reduction of fecal calprotectin levels induced by a short course of Escherichia coli nissle is associated with a lower likelihood of disease flares in patients with ulcerative colitis in clinical remission","volume":"33","author":"Pasta","year":"2024","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1128\/JB.183.8.2463-2475.2001","article-title":"The alternative electron acceptor tetrathionate supports B12-dependent anaerobic growth of Salmonella enterica serovar typhimurium on ethanolamine or 1,2-propanediol","volume":"183","author":"Price-Carter","year":"2001","journal-title":"J. Bacteriol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1039\/d0na00952k","article-title":"Nanomaterial-based encapsulation for controlled gastrointestinal delivery of viable probiotic bacteria","volume":"3","author":"Razavi","year":"2021","journal-title":"Nanoscale Adv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41467-022-28163-5","article-title":"Genetically stable CRISPR-Based kill switches for engineered microbes","volume":"13","author":"Rottinghaus","year":"2022","journal-title":"Nat. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3402\/mehd.v21i3-4.7512","article-title":"The non-pathogenic Escherichia coli strain nissle 1917\u2013features of a versatile probiotic","volume":"21","author":"Sonnenborn","year":"2009","journal-title":"Microb. Ecol. Health Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","article-title":"AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders","volume":"159","author":"Su","year":"2020","journal-title":"Gastroenterology"},{"key":"B29","unstructured":"Synlogic announces decision to discontinue Synpheny-3 study and provides corporate update\n          \n          \n          2024"},{"key":"B30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1099\/jmm.0.025874-0","article-title":"Testing probiotic strain Escherichia coli nissle 1917 (mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities","volume":"60","author":"Tannock","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ecco-jcc\/jjz051","article-title":"European crohn's and colitis organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease","volume":"13","author":"Torres","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1101\/2024.10.08.617317","volume-title":"Bio-engineering a common probiotic to exploit colonic inflammation promotes reliable efficacy in translational models of colitis","author":"Verdugo-Meza","year":"2024"},{"key":"B33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijfoodmicro.2010.03.037","article-title":"Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice","volume":"144","author":"Watterlot","year":"2010","journal-title":"Int. J. Food Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/s41591-019-0626-9","article-title":"Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients","volume":"25","author":"Yelin","year":"2019","journal-title":"Nat. Med."},{"key":"B35","unstructured":"Is the microbiome therapy hype up for a reckoning? Pharmaceutical technology\n          \n          \n            \n              Zamecnik\n              A.\n            \n          \n          \n          2023"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.cell.2018.08.041","article-title":"Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features","volume":"174","author":"Zmora","year":"2018","journal-title":"Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1695976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:21:57Z","timestamp":1762320117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1695976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":39,"alternative-id":["10.3389\/fphar.2025.1695976"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1695976","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1695976"}}